Colorectal cancer is the third most common cancer in the UK and while 5 year survival rates are 75% if the disease is detected early, they decrease sharply to 5% in advanced stage disease. Early diagnosis and treatment of colorectal cancer are essential in reducing mortality by detecting the cancer at an early stage. In the UK, there is currently a national screening programme for bowel cancer (the NHS Bowel Screening programme) which uses Faecal Occult blood test (FOBt) as a primary screening test followed by colonoscopy in those that test positive. However, although FOBt has encouraging sensitivity, the compliance with the test is only 50%. Therefore, there is an urgent need to develop a blood bases marker that would either improve compliance or improve the performance of the test.
Identifying biomarkers and risk factors for colorectal cancer
- John Timms (UCL), Usha Menon, Aleksandra Gentry-Maharaj (UCL)
Investigation of a cancer specific serum response in relation to the development of colorectal cancer
- Usha Menon (UCL), Hans Wandall (University of Copenhagen); Anne Dawnay (UCLH, UK) Aleksandra Gentry-Maharaj (UCL)
- Danish Council for Independent Research